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Cancer is a complex group of diseases that can be difficult to therapeutically
target as cancer cells develop a myriad of mechanisms to spread and survive.
Immune evasion is one such mechanism cancer cells use to bypass the immune
system and continue to invade other tissues. Evading the immune system is
achieved through over-expression of the immune checkpoint protein programmed
death ligand-1 (PD-L1). This protein is used as a predictive bio-marker to de-
termine whether cancer patients are viable for PD-L1 immunotherapy, and over-
expression of PD-L1 is determined using immunohistochemistry assays. Given
that these assays use different PD-L1 antibodies that recognise different epitopes,
it introduces variability to staining patterns and scoring matrices. This study has
taken advantage of the endogenous high affinity interaction between PD-L1 and
its receptor, programmed death receptor-1 (PD-1), to create a novel technique
to detect PD-L1 on the surface of cancer cells. Nucleosomal arrays were formed
with PD-1 peptide tagged to histone H2B containing octamers and fluorescently
labelled DNA. These nucleosomal assemblies had correct nucleosome formation
when using biotin-labelled positioning DNA and were able to be detected by bind-
ing Avidin-Alexa 488. These nucleosomal arrays bound specifically to PD-L1 on
the surface of cancer cells shown by fluorescent confocal microscopy and demon-
strated greater specificity than Wild Type H2B containing nucleosomal arrays.
The use of nucleosomal arrays in this manner has an advantage over an anti-
body as there are a greater number of PD-L1 binding sites, and the fluorescent
signal is able to be amplified due to positioning DNA being labelled at multiple
sites. Though this study used the PD-L1/PD-1 interaction as a proof of prin-
ciple, other short specific binding domains could be attached to the N-terminal
tail of histones that could detect other extracellular proteins. This novel detec-
tion method is efficient and specific, and further optimisation in other fluorescent
iii
detection platforms may yield a more consistent and high-throughput method





Due to COVID-19 and the resulting university closure in 2020 that meant lack
of laboratory access for 2 months, the stated objectives and experiments were
unable to be completed. These experiments included TEM imaging of PD-1/H2B
nucleosomal arrays (see Chapter Section 3.3), and FACS analysis of PD-1/H2B
and WT nucleosomal arrays (see Chapter Section 4.3). Due to the lack of time
to optimise these experiments, aim 3 (see Introduction Section 1.5) was unable
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Each year worldwide, approximately 9.5 million people die of cancer. Cancer not
only poses a health risk to individuals, but is also likely to have confounding
impacts on a patient’s socio-economic welfare and mental health. Cancer can be
diagnosed through biopsy, MRI, and X-ray, and treatment is usually dependent
on tumour type, malignancy, and tissue source, but can range from surgical re-
section to radiotherapy and chemotherapy. There is an increasing need for novel
treatments to specifically target cancer cells, though this can be difficult due to
the multitude of various mutations that can arise in a single tumour. Cancer
cells can arise by avoiding death signals and enhancing growth signals, as well
as avoiding DNA repair mechanisms. These traits were outlined in the paper by
Hanahan and Weinberg (2000). Through these means, tumour cells are able to
sustain their proliferative state and become increasingly intrusive within their en-
vironment. Emerging hallmarks of cancer have also been recently described such
as immune evasion (Hanahan and Weinberg, 2011). This is where cancer cells
are able to bypass the immune system by deactivating key immune checkpoint
pathways, one of which involves the protein programmed death ligand-1 (PD-L1).
1.2 Immune Evasion
The interaction between the immune system and cancer cells is complex, and this
complexity increases the difficulty in developing novel therapeutic drug treat-
ments. Some cancer cells are able to evade the immune system and metastasise
within other tissues by deactivating key immune checkpoint pathways to in order
to go undetected. Conditions that may facilitate the increased risk of immune
evasion by cancer cells are changes due to infection or chronic inflammation and
allow cancer cells to undergo what is known as ’immuno-sculpting’. This theory
describes how cancer cells are able to go from somatic cells to detectable cancer
cells. The theory, as described in the paper by Dunn et al. (2004), details the
three stages of this process (Figure 1.1).
In the first stage, cancer cells are eradicated by the immune system provided
that they express tumour-specific antigens to be targeted by immune cells such
3
Figure 1.1: The Three Stages of The Immuno-Sculpting Process. Represen-
tative image of the three stages of the immuno-sculpting process. (Dunn et al., 2004).
as CD8+ cytotoxic T cells and CD4+ helper T cells. The second stage, known
as equilibrium, describes how cancer cells which are not targeted by the immune
system lie dormant and have the ability to replicate variants that do not have
targetable antigens exposed. These cells may lie dormant for a certain period of
time before they re-emerge, or may not re-emerge at all if the patient’s immune
system is able to target them once more. In the third stage, escape, cancer cells
which have not been exposed to the immune system and have formed resistant
variants are able to escape the immune system and once again metastasise. This
can occur if certain cancer cells are not recognised by the immune system, if there
is down-regulation of the immune system, or excess inflammation. It should
be noted that even if a patient’s immune system is in full working order, it is
redundant if the cancer cells are no longer targetable. Regardless, these escaped
cells are able to once again excessively replicate and travel to other areas of the
body. Thus they have evaded the immune system completely.
The adaptive arm of the immune response is made up of numerous receptors
and their ligands, which help regulate antigen recognition within the emerging
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immune system and maintain self-tolerance. This occurs through immune check-
point pathways. During negative T-cell selection, T-cells that attack self-antigens
indiscriminately are deactivated or undergo apoptosis in order to prevent disad-
vantageous auto-immune reactions (Klein et al., 2014; Takaba and Takayanagi,
2017). Naïve T-cells are differentiated into cytotoxic CD8+ cells that function
to kill cancer cells, or helper CD4+ T-cells used to fight infections by releasing
cytokines used for signalling other immune proteins and pathways (Leonard and
Lin, 2000). This is based on major histocompatibility (MHC) class antigens cy-
tokines are presented with (Gutcher and Becher, 2007). This process is facilitated
through notable immune checkpoint proteins such as Cytotoxic T lymphocyte-
associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and
programmed cell death ligand-1 (PD-L1).
1.3 PD-L1 Immune Checkpoint Protein
PD-L1, otherwise known as B7 Homolog 1 or CD274, is a 33-40 kDa immune
checkpoint protein expressed on the surface of antigen-presenting L and B lym-
phocytes, a type of white blood cell that makes up part of the immune system.
It is a transmembrane glycoprotein part of the immunoglobulin super-family and
has characteristic extracellular Ig variable and Ig constant regions, followed by a
hydrophobic domain that spans the membrane, and an intracellular domain. It
is the variable regions of PD-L1 that interact with its receptor, PD-1, that leads
to T-cell exhaustion.
PD-L1 binds to the receptor PD-1, expressed on the surface of T cells and se-
lectively on Natural Killer (NK) cells to suppress the immune response (Butte
et al., 2007; Wang et al., 2016). PD-L1 binding to its receptor, PD-1, results
in deactivation of T-cells through the phosphorylation of two tyrosine residues
within the immunoreceptor tyrosine-based inhibitory motif (ITIM) located within
the cytoplasmic domain of PD-1 (Parry et al., 2005; Yokosuka et al., 2012). The
tyrosine-based inhibitory motif is found within immune system receptors in order
to attenuate cell signalling during immune cell activation (Barrow and Trows-
dale, 2006). Phosphorylation of the tyrosine residues may be through the action
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of lymphocyte-specific protein kinase (Lck) or C-terminal src-kinase but the spe-
cific mechanism is as yet unclear (Sheppard et al., 2004). This then deactivates
the T-cell antigen receptor (TCR) leading to T-cell apoptosis (Parry et al., 2005;
Yokosuka et al., 2012).
The PD-L1 activation pathway is complex and recruits numerous transcription
factors and kinases in order regulate PD-L1 expression. PD-L1 expression is
stimulated by Interferon-γ (IFN-γ) and nuclear factor kappa light chain en-
hancer of activated B cells (NF-κB) (Gowrishankar et al., 2015). IFN-γ is a
pro-inflammatory cytokine produced by NK cells and is a class II MHC molecule.
Binding to its receptors IFNγ Receptors 1 and 2 activates Janus kinase (JAK)
and signal transducer and activator of transcription (STAT) pathway in order
activate interferon regulatory factor 1 (IRF1) which then binds to the PD-L1
promoter region to bring about its transcription. The JAK-STAT pathway is
also able to recruit transcriptions factors such as MYC and NF-κB which are
able to bind to the promoter region of PD-L1 (Garcia-Diaz et al., 2017; Moon
et al., 2017). NF-κB is a transcription factor involved in cell survival and pro-
liferation. It exists in an inactive state in the cell until its activation is bought
about by IκB Kinase. In cancer cells, NF-κB is found to be constitutively active
and enhances the expression of genes needed for survival and proliferation, and
is an inhibitor of cellular apoptosis (Taniguchi and Karin, 2018).
PD-L1 over-expression has been found in a variety of cancer states including
glioblastoma (Berghoff et al., 2015; Xue et al., 2017), renal cell carcinoma (Thomp-
son et al., 2006), non-small cell lung carcinoma (Pawelczyk et al., 2019), and
urothelial carcinoma (Nakanishi et al., 2007). Over-expression of PD-L1 is linked
to poor cancer patient prognosis, particularly in the case of glioblastoma cancer
patients (Hao et al., 2020). Glioblastoma multiform (GBM) is an aggressive grade
VI brain tumour, whose patient survival is only expected to be 12-15 months after
diagnosis (Alifieris and Trafalis, 2015; Tang et al., 2019). It can often be difficult
to target these tumours due to the blood-brain barrier, and the location of the
tumour in the brain. Other studies have reported that over-expression of PD-
L1 is correlated with positive patient prognosis, and increased chance of survival
thus indicating the unpredictable nature of the signalling pathway (Gato-Cañas
et al., 2017). Studies conducted on different tumours have used PD-L1 expression
levels as a predictive bio-marker to determine not only patient prognosis, but also
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patient response to drugs targeting PD-L1. If a patient has undergone a PD-L1
expression test, they may be viable to undergo therapy with either PD-L1 or
PD-1 antibodies. Patients are able to undergo a PD-L1 IHC (immunohistochem-
istry) diagnostic assay in order to determine whether they are viable for antibody
therapy.
1.4 Immunohistochemistry assays
Immune evasion of cells is a relatively recent hallmark of cancer that emerged af-
ter well regarded characteristics such as evasion of death signals, and promotion
of growth enhancers. In order to suppress immune evasion of tumours in cancer
patients, pharmaceutical companies have developed PD-L1 and PD-1 therapies
that utilize antibodies that target the receptor-ligand interaction. IHC is utilized
to assess patient viability for PD-L1/PD-1 therapies (Diggs and Hsueh, 2017).
Those patients who exhibit over-expression of PD-L1 in tumour cells are recom-
mended treatment.
IHC assays are used to determine the expression levels of an antigen in a pa-
tient tissue sample using predictive bio-markers as targets. IHC staining involves
incubating a formaldehyde-fixed patient sample with a primary antibody: an an-
tibody that binds to the epitope of interest. This first antibody is then detected
by a secondary antibody that is tagged with horseradish peroxidase (HRP) or
Alkaline Phosphatase (AP). A chromogen such as 3,3’-diaminobenzidine (DAB)
reacts with the tag to produce a red-brown coloured reaction that is able to be
visualised. Brown deposits are indicative of positive staining (Ramos-Vara and
Miller, 2014). However, IHC assays are not quantitative unlike those utilizing
fluorophores where fluorescence can be measured.
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Figure 1.2: PD-L1 Antibody Staining. Representative PD-L1 staining using five
commonly used PD-L1 antibodies used in commercially available IHC assays. H & E,
haematoxylin and eosin staining. (Tsao et al., 2018).
There are a variety of IHC diagnostic kits available, each with their own detec-
tion antibody and specific scoring matrix. Each assay uses a specific splicing
variant, some of which are used for both detection and therapeutics. However, it
has become increasingly clear that there is lack of consistency between different
IHC kits (Kintsler et al., 2019). IHC standardisation can be hard to maintain,
especially between laboratories which have their own scoring criteria for patient
samples, and different staining protocols which can affect the outcome of a di-
agnostic assay. Two laboratories conducting IHC assays on the same patient
samples may score them differently such that one lab may determine a patient
needs a specific drug or therapy to target the protein or antigen of interest, while
an alternative lab may determine that the patient sample falls below their thresh-
old for therapy. This can compromise the health of the patient if they do not
receive the treatment they need. PD-L1 IHC assays are one example of how
these standardisation problems can severely affect a patient. Concerns have also
been raised about the sensitivity of each antibody used in each assay. Figure
1.2 shows that using different antibodies results in different staining intensities.
Antibodies 22C3, SP263 and 28-8 have comparable staining patterns, whereas
others such as 73-10 show much higher sensitivity to PD-L1. This indicates that
only certain PD-L1 antibodies are inter-changeable, but laboratories will only use
one PD-L1 antibody for IHC staining. It is apparent that a universal improved
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diagnostic reagent is needed in order to determine whether patients are viable for
PD-L1/PD-1 therapy.
Currently there are six antibodies that have been FDA approved for patients
requiring PD-L1/PD-1 therapy. These are described in Table 1.1. All therapies
share one common goal: to inhibit the interaction between PD-L1 on tumour cells
and PD-1 on T cells, thereby allowing the body to target the malignant cells via
other means such as NK cells that target tumour cells lacking MHC I molecules.
Increased levels of NK cells within tumour sites have lead to positive outcomes
(Marcus et al., 2014; Coca et al., 1997).




















Head and neck cancer
Cemiplimab 2018 PD-1
Myeloma
Squamous cell skin cancer
Lung cancer
Table 1.1: PD-1/PD-L1 Therapy Agents. Each agent is listed along with the
associated oncogenic states its use has been approved for in trials. NSCLC, non-small
cell lung cancer, * - this agent failed its phase 3 trial in bladder cancer in 2017.
Recent studies have also shown that combinatorial therapy using different treat-
ments for checkpoint inhibition is more favourable than a single treatments. Ip-
ilimumab is a monoclonal antibody that targets CTLA-4 that down-regulates
immune response much like PD-L1 (Buchbinder and Desai, 2016). In the case
of melanoma and NSCLC patients, the most common combination is Nivolumab
and Ipilimumab. Melanoma patients treated with both treatments had a me-
dian progression-free survival time of 11.5 months compared to the individual
Nivolumab group (6.9 months) and the Ipilimumab group (2.9 months), supports
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use of multiple agents to target aspects of immune evasion as a treatment option
(Hodi et al., 2018).
1.5 Chromatin
In order to fit all the information contained within the nucleus, cells condense
their DNA into a universal packaging system called chromatin. In 1974, Kornberg
published his seminal paper "Chromatin Structure: A Repeating Unit of Histones
and DNA" that detailed how DNA within the nucleus is compacted into repeating
units called nucleosomes which are made up of approximately 147 bp of DNA
wound around an octamer of histone proteins. An octamer contains two units of
histones H2A, H2B, H3, and H4, in which H2A and H2B form two dimers, and
H3 and H4 form a tetramer. Linker DNA approximately 80 bp is found between
the repeating octamer units, though this length depends on species. Repeating
nucleosomes thus make up a 10 nm nucleosome fibre. This fibre is often described
as a ’beads on a string’ structure (Baldi et al., 2020). Further compaction due to
super-coiling turns this 10 nm into a 30 nm fibre requiring a fifth histone, linker
histone H1. Higher orders of folding eventually result in the DNA compacted into
a chromosome. When cells are in interphase, chromatin can be separated into
highly compacted and gene suppressing heterochromatin, and loosely compacted
euchromatin that allows transcription factors to access genes. Domains regulated
by proteins interact with and modify histones to determine gene expression. The
ability of enzymes and proteins to access these areas is high regulated through
various means of chromatin regulator proteins such as heterochromatin protein
1, as well as chemical alterations to histone protein tails.
1.5.1 Histone Structure
Histone proteins range in molecular weight from approximately 11 kDa to 15 kDa,
with histone H4 being the smallest histone. All contain a characteristic histone
fold domain that is made up of a combination of three α-helices connected by two
loops (Arents and Moudrianakis, 1995). Additionally, histone proteins contain an
unstructured N and C terminal tails that contribute significantly to nucleosome
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stability through the action of post-translational modifications, particularly the
N-terminal tail (Ng et al., 2009). Furthermore, these tails protrude from the core
nucleosome structure which allows them to be targeted by modifying enzymes
that modulate gene expression. The combination of post-translational modifica-
tion and their reversibility is what makes up the epigenetic code, and allows for
differential gene expression. The N-terminal tails of histones are a highly con-
served feature and can be found in many different organisms ranging from yeast
to humans. However, these N-terminal tails contain no structured domains, and
hence their ability to regulate gene expression comes from post-translational mod-
ifications such as acetylation and methylation (Bannister and Kouzarides, 2011).
These chemical changes to residues within histone tails allows them to be more
or less compacted to the overall nucleosome structure. More compaction means
histones are wound tighter around the DNA. This prevents transcription fac-
tors from being able to access the DNA, and thus gene expression is repressed.
Modifications such as acetylation decreases the negative charge on histone tails,
reducing the electrostatic interaction between them and negatively charged phos-
phate groups of DNA (Morales and Richard-Foy, 2000).
Though each histone is highly conserved in nature, there are variants that exist in
other species, as well as different isoforms that act as substitues for core histone
proteins. Specific histones are required for transcription activation or repression,
and histones are interchanged through a variety of means, but usually through
the action of ATP-dependent chromatin remodellers such as SWI/SNF (Tang
et al., 2010). Gene expression modulation through the action of nucleosome posi-
tioning and histone exchange determines how available DNA is for transcription.
An example of this is histone variant H2A.Z, a variant of histone H2A. Studies
have shown that this variant is involved in both transcriptional activation and re-
pression, a unique characteristic unlike other histone variants, but also has other
roles in DNA repair, differentiation, and T-cell formation (Rudnizky et al., 2016;
Giaimo et al., 2019).
Histone proteins can be easily expressed in an E.coli system and purified from bac-
terial inclusion bodies which are protein aggregates that contain a high concentra-
tion of the histones. Inclusion bodies undergo ion exchange chromatography and
are unfolded using unfolding buffer containing guanidinium hydrochloride, after
which they are subjected to further ion exchange chromatography. Fractions of
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interest are pooled and dialysed against distilled water and purified histones can
then be reconstituted into histone octamers via dialysis in urea refolding buffer
(Rogge et al., 2013; Kintsler et al., 2019). The N-terminal tails of histones are ex-
posed on the outside of the nucleosome and their unstructured nature provides a
scaffold for attachment of desired ligands without adversely affecting nucleosome
structure (de la Barre et al., 2001).
1.5.2 Nucleosomal Array Structure
In order to make nucleosomal arrays, a nucleosome positioning sequence is used in
order to help orientate histone octamers into correct positioning (approximately
200 bp between each nucleosome). A nucleosome positioning sequence is the lo-
calisation of DNA relative to the histone octamer. In vivo, there are sequences
which favour nucleosome assembly at a certain length of DNA, and these se-
quences act to stabilise the entire nucleosome. This stability determines how
likely a nucleosome is adverse to change depending on the conditions and stimuli
it experiences. The more nucleosome positioning sequences that are available, the
more repeating monomers are able to be formed (the number of repeating units
are known as mers). Any length of nucleosomal arrays are able to be formed,
including mono, di, and tri-nucleosomal arrays. Producing nucleosomal arrays in
vitro requires DNA and histone octamers. Nucleosome positioning is a dynamic
process, and there are many different in vitro sequences available for nucleosome
structural studies. The most famous of these is the non-endogenous Widom 601
sequence formed by Widom and colleagues in 1998 (Lowary and Widom, 1998).
This sequence is made up of approximately 220 bp, of which 147 bp form the high
affinity binding site for octamers. This core sequence is flanked by two linker se-
quences either side for additional nucleosomes. There are other variations of this
sequence such as 601.2 which is 174 bp and incorporates a restriction site, and
other sequences such as the 5s rDNA sequence, a 260 bp sequences isolated from
the 5s ribosomal RNA gene of Lytechinus variegatus.
TheWidom 601 nucleosome positioning sequence shown in Figure 1.3 was founded
using systematic evolution of ligands by exponential enrichment (SELEX). A ran-
dom pool of chemically synthesised DNA fragments were tested for their affinity
to bind histone octamers. Fragments that had high affinity for octamers were
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Figure 1.3: Widom 601 Nucleosome Positioning Sequence. The Widom 601
nucleosome positioning sequence, founded using SELEX experiments, is made up of
approximately 220 bp. Bases shown in red are used to position the histone octamer
with 78 bp of linker DNA leading to the next nucleosome positioning sequence.
cloned, sequenced and tested for their ability to form nucleosomes. From this,
the Widom 601 sequence was founded. DNA and histone octamer titrations are
needed in order to determine what the correct molar ratios are to make a correctly
spaced array, and this is also determined by the assembly method used. The first
method of nucleosomal array assembly involves dialysing the assembly in progres-
sively lower concentrations of salt buffer ranging from 1 M salt to 150 mM salt in
order to promote DNA-octamer interaction. The second method involves making
the assembly and progressively adding dilution buffer to the assembly reaction
mixture in order to dilute the salt (Flaus, 2011).
In this study, the extracellular domain of PD-1 receptor (amino acids 118-139)
was attached to the end of the N-terminal tail of histone H2B in order to target
PD-1/H2B nucleosomal arrays to PD-L1 expressed on the surface of cancer cells.
This histone was chosen as the H2A-H2B dimers are found on the surface of the
histone octamer, rather than the H3-H4 tetrameric core as shown in Figure 1.4
(Arents et al., 1991). A pUC19 plasmid containing 16 repeats of the Widom
601 nucleosome positioning sequence (16 mer) will be used and optimised to be
fluorescently detected. The nucleosomal arrays formed in this study will have 32
binding sites available to bind to PD-L1. As the nucleosomes are identical repeat-
ing units, this will provide better specificity of binding to PD-L1 compared to an
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Figure 1.4: Nucleosome Core Particle Structure at 2.8Å Luger structure of the
nucleosomal core particle at 2.8 Å The DNA double helix is wound 1.65 times around
the histone octamer core. Two copies of each histone are shown inside the nucleosome
as red, yellow, blue, and green. N-terminal tails of the histone octamer core are shown
outside the nucleosome particle. This figure is adapted from Luger et al. (1997).
antibody that contains two epitope binding sites. As the nucleosome positioning
DNA will also be fluorescently detected, this will allow signal amplification so
that nucleosomal arrays can be easily detected on the cell surface. Nucleosomal
arrays are able to be efficiently made in vitro, are cost-effective to create, and are
easily modifiable due to the nature of the unstructured histone tails.
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1.6 Objectives
Due to the inconsistency in scoring matrices in determining PD-L1 expression
levels in patient tumour samples, it is evident that a new reliable diagnostic
technique is needed to help patients determine whether they are viable for PD-
L1 immunotherapy. To our knowledge, no one has attempted to use nucleosomal
arrays as an effective method for detecting extracellular proteins.
We hypothesise that forming a nucleosomal array with a PD-1 derived peptide
onto a core histone N-terminal tail and fluorescently detectable DNA is an effec-
tive novel diagnostic technique for detecting PD-L1 on cancer cells.
The aims of this study are to:
1. To create nucleosomal arrays with PD-1 peptide octamers and labelled
DNA.
(a) Purify histones and assemble into octamers.
(b) Fluorescently detect nucleosome positioning DNA.
2. To test binding of nucleosomal arrays.
3. Comparison of nucleosomeal arrays to diagnostic PD-L1 antibody.







2.1 Tissue Culture Methods
2.1.1 Cell Line Maintenance
U87-MG, LN18, U2OS, MCF-8, H1299, and HeLa cells were grown at 37°C
in 5% CO2 in 100 mm plates in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% v/v Foetal Bovine Serum (FBS) and 0.5% penicillin-
streptomycin. Cells were passaged approximately every 3-5 days. Prior to pas-
sage, growth medium (DMEM) and 0.05% v/v Trypsin/EDTA were warmed at
37◦C. Old growth medium was removed from the plates, which were then washed
with 10 mL of PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, pH 7.4). After removal, cells were treated with 1 mL of Trypsin/EDTA
which was then immediately removed. Cells were incubated for approximately
1-2 minutes, after which cells were dislodged by gently tapping on the plates.
Dislodged cells were then resuspended in growth medium at a 1:16 dilution fac-
tor.
2.2 RNA Extraction
U87-MG, LN18, U2OS, MCF-7, H1299, and HeLa cells were grown to 80% con-
fluency and the growth medium removed. Cells were washed and scraped with
1 mL PBS, after which they were centrifuged at 3000 rpm for 5 minutes at 4◦C.
Supernatant was discarded and the cell pellet was resuspended in 800 µL of PBS.
From this cell suspension, 100 µL was taken out and placed in a separate tube,
to which 300 µL of TRIzol® was added. RNA was then extracted using the
Direct-zolTM RNA MiniPrep kit (ZymoResearch). RNA was quantified using the
DeNovix DS-11 Spectrophotometer.
2.3 RT-qPCR
Real-time quantitative polymerase chain reaction (RT-qPCR) was performed us-
ing RNA extracted from U87-MG, LN18, U2OS, MCF-7, H1299, and HeLa cells
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(see Section 2.2. Extracted RNA was reversely transcribed to cDNA using the
SensiFAST™ SYBR® No-ROX One-Step Kit (Bioline) using primers provided
by QAIGEN (PD-L1: QT00082775, GUSB: QT00046046). RT-qPCR data was
obtained using Roche 480 Lightcycler software. The program was set as follows:
1 cycle at 95◦C with a 5 minute hold followed by 12 cycles at 37◦C with a 5
second hold. Fluorescence readings were only taken during the 12 cycle period.
2.4 Protein Extraction
Cells were grown to 80-100% confluency before the growth media was removed
and cells were washed with 1 mL of PBS before being scraped from each plate.
Cells were then centrifuged at 600g for 5 minutes at 4◦C before washing once
with PBS. Cell were centrifuged again and cell pellets were resuspended in 500
µL RIPA buffer (150 mM Nacl, 1% Igepal CA-630, 0.5% DOC, 0.1% SDS, 50 mM
Tris pH 8.0, 1 cOmpleteTM ULTRA Mini Protease Cocktail Inhibitor tablet) and
incubated on ice for 30 minutes. Cell lysates were then centrifuged at 14000 xg
for 10 minutes at 4◦C and the supernatant collected. Protein concentration were
determined using the DeNovix DS-11 Spectrophotometer.
2.5 Plasmid Preparation and Purification
2.5.1 Plasmid Preparation
Transformation was carried out using competent E. coli DH5α cells (Invitrogen)
(EPA approval number GM009, MU001). Cells were incubated with 0.5 µg of
plasmid and incubated on ice for 30 minutes followed by heat shock at 42◦C for
45 seconds. Reaction mixtures were placed on ice for a further 2 minutes after
which 500 µL of sterile S.O.C medium was added. Transformation mixtures were
incubated at 37◦C for 1 hour with shaking at 250 rpm. Transformation mixtures
were then centrifuged at 5000 rpm and 450 µL of supernatant removed. Cells were
resuspended in 50 µL and transferred onto LB agar plates supplemented with 100
µL/mL of ampicillin, after which plates were incubated at 37◦C overnight.
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2.5.2 Plasmid Purification
After transformation of E. coli DH5α, a single colony was picked and inoculated
into 5 mL of LB supplemented with ampicillin (100 µg/mL). After five hours
of incubation at 37◦C with shaking at 250 rpm, 500 µL of starter culture was
added to 100 mL of LB supplemented with 100 µg/mL of ampicillin and left to
grow overnight at 37◦C with constant shaking. Plasmids were then extracted
using either the Qiagen Plasmid Midi-Kit, or the GeneJET Plasmid Midiprep
Kit (Thermofisher). The concentration of purified plasmid was then determined
using DeNovix DS-11 Spectrophotometer at 260 nm.
2.6 Histone Expression and Purification
2.6.1 Histone Expression
Homo sapien core histone proteins were grown in 500 mL of LB broth supple-
mented with T broth buffer (0.17 M KH2PO4, 0.72 M K2HPO4), 20% glucose, and
100 µg/mL of ampicillin at 37◦C with shaking at 200 rpm until OD600 reached
0.4-0.6. Cells were then induced with 0.25 mM of IPTG for 2 hours at 37◦C.
Pellets were harvested at 5000 rpm for 15 minutes at 4◦C and stored at -80◦C
until purification.
2.6.2 Histone Purification
E. coli BL21 cell pellets were washed with W buffer (50 mM Tris-Cl pH 7.5, 100
mM Nacl, 1 mM 2-mercaptoethanol), after which 50 units of DNase I and 10
mM of MgCl2 was added before the pellet was sonicated at 25% amplitude for 2
seconds on and 8 seconds off for 1 minute. Lysates were then centrifuged at 25K
g at 4◦C for 20 minutes and combined with WT buffer (W buffer + 1% Triton-X
100 (v/v)). Lysates were then resuspended with 7 M guanidinium HCl solution
(7 M guanidinium HCl, 20 mM NaOAc pH 5.2, 1 mM DTT) and left to incubate
overnight to unfold histone proteins. After overnight incubation, cell suspensions
were centrifuged at 25K g at 4◦C for 20 minutes and separated on a Superdex
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S-200 ion exchange column (Sigma Aldrich).
Fractions of interest were combined and dialysed with urea buffer (7 M urea, 20
mM NaOAc pH 5.2, 1 mM DTT) overnight. Proteins were then further separated
on a disposable column with sequential addition of 10 mL of S100-S1000 buffers





























20 mM NaOAc pH 5.2
1000 mM NaCl
2 mM BME
Table 2.1: Salt Gradient Buffer Compositions. Buffer S100-S1000 were made
and 10 mL was added sequentially to the disposable column as in section 2.5.2.
After protein separation, fractions of interest were combined and dialysed in 3 L
of water containing 2 mM of BME at 4◦C overnight. Samples were centrifuged
at 30K g for 20 minutes at 4◦C and were then lyophilised.
2.6.3 Histone Octamer Reconstitution
Purified histone proteins were combined in equimolar ratios and rotated at 4◦C
for 1 hour, after which they were centrifuged at full speed for 30 minutes at 4◦C.
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Histone octamers were then resolved using a Superdex S-200 column in refolding
buffer (7 M guanidinium HCl, 20 mM Tris, pH 7.5, 10 mM DTT). Fractions of
interest were combined, concentrated, dialysed in storage buffer (10 mM Tris-Cl,
1 mM EDTA, 2.5 mM NaCl, 25%glycerol, 2 mM BME). Octamer concentration
was measured using BSA standards, aliquoted, and stored at -80◦C.
2.6.4 SDS-PAGE
For sodium dodecyl sulfate (SDS) poly-acrylamide gel electrophoresis (PAGE),
firstly a 12% acrylamide:bis-acrylamide resolving gel was made using 375 mM of
Tris-Cl (pH 8.8), 0.1% ammonium persulfate (APS), 0.1% SDS and 0.1% tetram-
ethylethylenediamine (TEMED). A 4% acrylamide:bis-acrylamide stacking gel
was made using 125 mM of Tris-Cl (pH 6.8), 0.1% APS, 0.1% SDS and 0.1%
TEMED. Once the resolving gel has polymerised, the stacking gel was poured on
top and also left to polymerise.
6x SDS-loading buffer (62.5 mM Tris-Cl pH 6.8, 1.67% SDS, 7.5% glycerol, 0.01%
bromophenol-blue, 35.75 mM 2-mercaptoethanol) was added to samples at a final
concentration of 1x. Samples were heated to 95◦C for 5 minutes, after which they
were centrifuged and resolved on a 12% acrylamide gel in 1x TGS buffer (25 mM
Tris-Cl, 192 mM glycine, 0.1% SDS) at 40 mA for 1 hour.
2.6.5 Coomassie Staining
After resolving samples in a 12% acrylamide gel for 1 hour, gels were washed with
distilled H2O and fixed with 30% methanol and 10% acetic acid. They were then
stained with Coomassie blue overnight and destained with distilled H2O.
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2.7 In Vitro Nuclesomal Array Assembly
2.7.1 Nucleosome Array Assembly
PD-1 derived peptide (MSGTYLCGAISLAPKAQIKESLR) translationally fused
to histone H2B N-terminal tail (pET3 plasmid GenScript) were expressed in E.
coli BL21 cells. Recombinant and unmodified histones were purified according
to section (2.5.2). Histones were combined in equimolar ratios and dialysed
in refolding buffer (10 mM Tris, 2 M NaCl, 1 mM EDTA, and 1 mM BME).
PD-1/H2B octamers and pUC19 plasmid containing 16 repeats of the Widom
601 nucleosome positioning sequence were mixed using different volumes of PD-
1/H2B octamer to 1 µg of DNA and dialysed in 1 M NaCl dialysis buffer (10
mM Tris-Cl pH 7.5, 1 mM EDTA, 1 M NaCl, 10 mM 2-mercaptoethanol) for
5-6 hours at 4◦C, after which it was dialysed 0.75 M dialysis buffer overnight (10
mM Tris-Cl pH 7.5, 1 mM EDTA, 0.75 M NaCl, 10 mM 2-mercaptoethanol).
Assemblies were then dialysed in PBS overnight twice at 4◦C, after which they
were collected and stored at 4◦C.
2.7.2 Micrococcal Nuclease Digestion of Nucleosomal Ar-
rays
For each nucleosomal assembly made, an micrococcal nuclease (MNase) digestion
was performed. From each assembly, 1 µg of nucleosomal array was made up to
200 µL with PBS, after which 1 µL of 250 mM CaCl2 was added. This was then
split into two tubes of 100 µL and incubated at 30◦C for 10 minutes. To these
tubes, 0.5 µL or 2 µL of MNase (Roche) diluted 1:2000 in salt dilution buffer II
(10 mM Tris pH 7.5, 1mM EDTA, 0.1% v/v NP-40, 5mM DTT, 0.5 mM PMSF,
20% v/v glycerol, 100 µg/mL BSA) was added and incubated for a further 10
minutes at 30◦C. After incubation, digestion was stopped by adding 300 µL of
glycogen stop buffer (20 mM EDTA, 0.2M NaCl, 1% v/v SDS, and 0.25 mg/mL
glycogen), 1 µL of 50 mg/mL Proteinase K, and 16 µL of 250 mM EGTA to
each reaction. This was incubated overnight at 37◦C, after which 25 µL of 5 M
NH4AC was added, and DNA was extracted using 1:1 phenol and chloroform.
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DNA was then ethanol precipitated and centrifuged at max speed for 15 mins at
4◦C. Pellets were resuspended in TE buffer (10 mM Tris-Cl, 1 mM EDTA) and
electrophoresed on 1.2% agarose gel. DNA bands were visualised using ethidium
bromide (EtBr) and imaged with a UV transilluminator.
2.8 Microscopy Techniques
2.8.1 Acid etching and Poly-D-lysine Coverslip Coating
Coverslips (Electron Microscopy Sciences 8 mm Diameter, #1.5 Thickness) were
first incubated in 1M HCl overnight at 60◦C in a covered beaker. The next day,
they were washed with sterile dH2O to remove excess acid. Coverslips were then
incubated with 1 mg/mL of poly-D-lysine (Sigma-Aldrich) for 1 hour at room
temperature on a shaker. Coverslips were washed 3 x with sterilised dH2O, 2 x
10 minutes 70% EtOH, and lastly 2 x 10 minutes with 100% EtOH. After drying
on filter paper, coverslips were UV treated in a laminar flow hood for 20 minutes
on each side, after which they were stored at 4◦C with minimal disruption.
2.8.2 Immunofluorescence
U87-MG and MCF-7 were seeded on top of poly-D-lysine coated coverslips in a 6-
well plate at a density of 2.5 x 105 cells/well and left overnight to grow. Cells were
washed 2 x for 3 minutes PBS (+MgCl) at room temperature, and subsequently
fixed with 4% paraformaldehyde (in PBS) for 15 minutes and washed 2 x 10
minutes with PBS. Cells were then permeabilised using 2 mL of 1x PBS containing
0.5% Triton-X for 5 minutes and washed again with PBS. After transferring
coverslips to a 24-well plate, they were incubated with blocking buffer (10% BSA,
0.5% Tween-20, 1x PBS) for 30 minutes. Cells were washed 2 x 3 minutes in PBS,
after which they were incubated overnight at 4◦C with primary antibody (Dako
Anti-PD-L1 antibody [28-8], Abcam) diluted 1:350 to 2.85 µg/µL in blocking
buffer. After overnight incubation, excess primary antibody was removed and
cells were washed 3 x 5 minutes with wash buffer (1x PBS, 0.1% Triton-X) and
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incubated with secondary antibody diluted 1:500 in blocking buffer (Goat Anti-
Rabbit IgG H&L Alexa Fluor® 555, Abcam) for 1 hour at room temperature.
Cells were then washed 3 x 5 minutes in wash buffer and 1 x 5 minutes in PBS,
and were then fixed with 2% paraformaldehyde for 15 minutes. After washing 2
x 5 minutes with PBS, the coverslips were then mounted using SlowFade® Gold
Antifade Mountant with or without DAPI counterstain.
2.8.3 Fluorescent Labelling of PD-1/H2B Nucleosomal Ar-
rays
U87-MG and MCF-7 cells were seeded on top of poly-D-lysine coated coverslips in
a 6-well plate at a density of 2.5 x 105 cells/well and left overnight to grow. Cells
were washed 2 x for 3 minutes PBS (+MgCl) at room temperature, and subse-
quently fixed with 4% paraformaldehyde (in PBS) for 15 minutes and washed 2 x
10 minutes with PBS. If permeabilisation was required, cells were permeabilised
using 2 mL of 1x PBS containing 0.5% Triton-X for 5 minutes and washed again
with PBS. After transferring coverslips to a 24-well plate, they were incubated
with blocking buffer (10% BSA, 0.5% Tween-20, 1x PBS) for 30 minutes. If her-
ring sperm DNA was used, it was at this step and diluted to 100 µg/mL in blocking
buffer. Before application to cells, 1 µg of nucleosomal array was preincubated
with 2 µg/ml of NeutriAvidinTM Oregon GreenTM 488 conjugate (Thermofisher)
for 2 hours at room temperature. Cells were washed 2 x 3 minutes in PBS and
subsequently 3 x 5 minutes in wash buffer, after which they were incubated with
1 µg of array-Avidin-488 conjugate for 1 hour. Excess nucleosomal array was
removed, and cells were washed 3 x 5 minutes with wash buffer and 1 x 5 minutes
in PBS. Stained cells were then fixed with 4% paraformaldehyde (in PBS) for
15 minutes and washed 2 x 5 minutes with PBS. If cells were unpermeabilised,
they were firstly counterstained with Hoescht 3342 to image the nuclear DNA,
and mounted using SlowFade® Gold Antifade Mountant without DAPI. Perme-
abilised cells were mounted with SlowFade® Gold Antifade Mountant containing
DAPI.
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2.9 Alternative Detection Methods
2.9.1 Fluorescence Capture Through Roche 480 Lightcy-
cler Software
U87-MG cells were grown to 80-90% confluency, after which they were harvested
and diluted to 5 x 106 cells/mL. Cells were centrifuged at 220g for 5 minutes and
resuspended in PBS, after which 100 µL of cells were incubated with either 0, 0.1
µg, 0.5 µg, 1 µg, 2 µg, or 5 µg of PD-1/H2B-Cy5 nucleosomal array or wild-type-
Cy5 nucleosomal array. Cells were incubated at room temperature in the dark
for 2 hours, after which cells were washed with PBS and centrifuged at 380g for 5
minutes. Cells were resuspended in a final volume of 50 µL and fluorescence was
captured using the Roche 480 Lightcycler. The Cy5 filter (615-670 nm) was used
as the Cy5 fluorophore excites at 649 nm and emits at 666 nm. The program was
set as follows: 1 cycle at 95◦C with a 5 minute hold followed by 12 cycles at 37◦C
with a 5 second hold. Fluorescence readings were only taken during the 12 cycle
period.
2.9.2 Fluorescence Activated Cell Sorting (FACS)
U87-MG and MCF-7 cells were grown to 80-90% confluency, harvested, and re-
suspended at a density of 5 x 105 cells/mL. Cells were centrifuged at 220g for
5 minutes and resuspended in PBS, after which 100 µL of cells were incubated
with either with 0.1 µg, 0.5 µg or 1 µg of PD-1/H2B-Cy3 nucleosomal arrays for
2 hours in the dark at room temperature, after which cells were centrifuged at
380g for 5 minutes, fixed using 4% paraformaldehyde, and washed once more.
Cells were resuspended in a final volume of 1 mL before cell populations were
separated using the MoFlo XDP Cell Sorter at a flow rate of 50 µL/min. The
R-phycoerythrin (PE) filter (Ex 566 nm Em 574) was used to detect the Cy3
fluorophore and the fluorescein (FITC) filter (Ex 490 nm, Em 525 nm) was used
to detect any fluoresence emitted at a smaller wavelength.
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Chapter 3




3.1 Histone Expression and Purification
To create the PD-1 tagged H2B nucleosomal arrays required the expression of
PD-1/H2B and the other core histones, labelling of the nucleosomal positioning
DNA and formation of nucleosomal arrays. To obtain purified chimeric PD-
1/H2B histone, initially the PD-1/H2B expression vector was created by cloning
the PD-1 cDNA fragment (amino acid 118-139) in front of the H2B sequence in a
pET3a vector. This was done by Dr. Jeong Park. Histone H2B was chosen as it
is located on the surface of the histone octamer dimerised with histone H2A, as
opposed to either histones H3 or H4 which form the histone octamer core (Arents
et al., 1991). The amino acid sequence and schematic diagram of the chimeric
PD-1/H2B is shown in Figure 3.1.
Figure 3.1: Chimeric Histone H2B Sequence and Structure. A, Amino acid
sequence of histone H2B with PD-1 amino acids 118-139 insertion indicated in red.
PD-1 peptide was inserted after the first amino acid, M, of histone H2B. B, schematic
diagram of chimeric histone H2B.
Histones were then expressed and purified so histone octamers containing H2A,
PD-1/H2B, H3, and H4 could be formed. This was done according to previ-
ously established methods (Kintsler et al., 2019) (see Section 2.5). The following
figures are from the expression and purification of histone H4 as histones H2A,
PD-1/H2B, and H3 were previously purified by Dr. Jeong Park. H4 histone plas-
mid vector (pET3a-H4) was obtained from Genecript and expressed in E. coli
DH5α cells. E. coli cells were transformed with pET3-H4 plasmid, expressed and
induced with IPTG, and proteins were resolved using SDS-PAGE (Figure 3.2).
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Figure 3.2: Induction of H4 Expression. E. coli was transformed with H4 expres-
sion vector (pET3a-H4) and induced with 0.25 mM of IPTG for 2 hours after which
it was harvested. Samples of whole cell before and after induction was resolved on a
12% SDS-PAGE and stained with Coomassie blue (see Section 2.5.4 and 2.5.5). The
expected molecular weight of histone H4 is approximately 11 kDa.
After induction of H4 expression, the bands which ran at approximately 12 kDa
are darker indicating that histone H4 had been expressed. Cells were then soni-
cated and centrifuged to collect soluble (supernatant) and insoluble (pellet) frac-
tions. After resolution on a 12% SDS-PAGE, this indicated that H4 was present
in the cell pellet and whole sonicate as only these two lanes have visible bands
(Figure 3.3).
30
Figure 3.3: Histone H4 is Found in the Pellet. After harvesting, cell pellets were
resuspended in W buffer and sonicated at 25% amplitude for 1 minute. Samples were
centrifuged and 10 µL of sample was resolved on a 12% SDS-PAGE and stained with
Coomassie blue. Protein ladder was run adjacent to samples.
Histones were then denatured using guanidinium hydrochloride after which ion
exchange chromatography was performed using a SP Sepharose s200 column (see
Section 2.5.2).
Figure 3.4: S-200 Superdex H4 Histone Fractions. After histone inclusion bodies
were separated and histones unfolded using guanidinium hydrochloride, the histone H4
sample was applied to a S-200 Superdex column and resolved at 0.2 mL/min in 3
mL fractions. Fractions were separated on using a 12% SDS-PAGE and stained with
Coomassie blue. Protein ladder was run adjacent to samples.
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Fractions of interest (29-34) were combined (Figure 3.4), dialysed in urea buffer
and passed over a disposable ion exchange column using six different salt buffers
applied in order of increasing salt concentration. Composition of these buffers is
detailed in Table 1.1 in Section 2.5.2. Once this had been completed, histone
fractions were dialysed in urea buffer and lyophilised for storage.
Figure 3.5: Ion Exchange H4 Elutions. H4 samples were applied to an ion exchange
column and subjected to different salt gradient buffers to elute histone H4. From each
elution, 10 µL was taken and resolved on a 12% SDS-PAGE and stained with Coomassie
blue. Protein ladder was run adjacent to samples.
After purifying H4 with ion exchange chromatography, purity was then checked
by resolving different amounts of histone H4 on a 12% SDS-PAGE, alongside
previously purified histone H3 (Figure 3.6). One band was seen in each of the
histone H4 lane indicating that it has been purified.
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Figure 3.6: Purified Histone H4. To check for histone purity, 10, 20, and 30 µg of
histone H4, and 30 µg of histone H3 were resolved on a 12% SDS-PAGE and stained with
Coomassie blue. Protein ladder was run adjacent to samples. The expected molecular
weights of histones H4 and H3 are 11 kDa and 15 kDa respectively.
To begin histone octamer reconstitution, each purified histone was first dialysed
in unfolding buffer (see Section 2.5.3). Histones H2A and H2B were then mixed
in equimolar ratios to form dimers, as were histones H2B and PD-1/H2B. The
same process was done with histones H3 and H4 to form tetramers (Figure 3.7).
The full gel image of Figure 3.7 is shown in Figure A.1.
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Figure 3.7: Purified H2A-H2B Dimers and H3-H4 Tetramers. Histone proteins
were mixed in equimolar ratios to make the indicated dimers and tetramers. All samples
were diluted to 40 mM and 1 or 2 µg were resolved on a 12% SDS-PAGE and stained
with Coomassie blue. Protein ladder was run adjacent to samples. H2A-H2B-N-PD-
1, PD-1 ligand peptide attached to the N-terminal of H2B. The expected molecular
weights of histones H4, H3, H2A, and H2B are 11 kDa, 15 kDa, 14 kDa, and 14 kDa for
each histone respectively. Lanes not relevant to this study have been removed during
image processing. The full gel image of Figure 3.9 is shown in Figure A.1.
After the H2A PD-1/H2B dimers and H3-H4 tetramers were combined to form oc-
tamers, they were then dialysed in refolding buffer, centrifuged, and concentrated.
PD-1/H2B histone octamers were then purified on a Superdex-200 column and
the histone octamers eluted, after which their concentration was measured using
the DeNovix DS-11. Fractions of interest (22-35) were then pooled, concentrated,
then dialysed in final dialysis buffer (Figure 3.8) (see Section 2.5.3).
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Figure 3.8: PD-1/H2B Histone Octamer Fractions. After mixing H2A-H2B-N-
PDR dimers and H3-H4 tetramers in equimolar ratios, samples were purified using a
S-200 Superdex column at 0.1 mL/min at 1 mL fractions. From each fraction, 10 µL
was taken and resolved on a 12% SDS-PAGE and stained with Coomassie blue. Protein
ladder was run adjacent to samples. The expected molecular weights of histones H4, H3,
H2A, and H2B are 11 kDa, 15 kDa, 14 kDa, and 14 kDa for each histone respectively.
Purified PD-1/H2B histone octamers were resolved on a 12% SDS-PAGE. In
Figure 3.9, four bands can be seen when using the highest sample amount of PD-
1/H2B histone octamers. The four bands represent the four histone proteins used
to form the octamers. These four bands run from approximately 15 kDa to 21
kDa. WT octamers that contain untagged histone H2B were formed previously
by Dr. Jeong Park.
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Figure 3.9: Purified PD-1/H2B Histone Octamers. After PD-1/H2B histone
octamers were purified, 0.25, 0.5, 1.00, 1.25, and 1.50 µg of PD-1/H2B octamer was
separated using 12% SDS-PAGE and stained with Coomassie blue. Protein ladder was
run adjacent to samples. The expected molecular weights of histones H4, H3, H2A, and
H2B are 11 kDa, 15 kDa, 14 kDa, and 14 kDa for each histone respectively. Lanes not
relevant to this study have been removed. The full gel image of Figure 3.9 is shown in
Figure A.2.
3.2 Formation of the PD-1/H2B Nucleosomal Ar-
rays
To determine the optimal ratio of DNA to histone octamers, nucleosomal assem-
bly titrations were performed then analysed by Micrococcal nuclease (MNase)
digestion to confirm phased nucleosomes. MNase is an endonuclease that digests
DNA non-specifically between the linker regions of histones (Heins et al., 1967).
This produces a ladder of descending single, double, and poly-nucleosomes if
nucleosomes are properly positioned.
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Nucleosomal arrays were assembled using 1 µg of pUC19 DNA containing 16 re-
peats of the Widom 601 nucleosome positioning sequence and increasing amounts
of PD-1-H2B histone octamers ranging from 0.25 µg to 1.25 µg. Two different
concentrations of MNase were used to ensure partial digestion of the arrays.
Figure 3.10: Micrococcal Nuclease Digestion of Assembled Nucleosomal Ar-
rays. Nucleosomal arrays were made using 1µg/µL of un-labelled pUC19 plasmid DNA
containing 16 repeats of the Widom 601 nucleosome positioning sequence and increasing
amounts of PD-1-H2B histone octamers. After mixing, arrays were dialysed in decreas-
ing salt gradient buffers and digested with 0.5 and 2 U/µL of MNase. DNA fragments
were resolved on a 1.2% agarose gel and stained with ethidium bromide. DNA ladder
was run adjacent to the samples.
As seen in Figure 3.10, using 0.75 µg of histone octamer to 1 µg of DNA creates the
most discernible DNA ladder which reflects properly spaced nucleosomes (lanes
5 and 6) and gives a similar ladder to a nucleosomal array with untagged histone
(Voong et al., 2017). A lower amount of histone octamer (0.25 µg) results in
little discernible ladder indicating this concentration of core histones results in
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an array undersaturated with nucleosomes as the nucleosomes are too distantly
spaced resulting in indiscriminate cleavage by MNase (lanes 1 and 2). In lanes
9 and 10, no ladder can be seen when using a histone octamer amount of 1.25
µg, indicating the array is over-saturated with histones. Therefore nucleosomal
arrays containing 0.75 µg of PD-1-H2B histone octamers per 1 µg of nucleosomal
positioning plasmid DNA were used for the remainder of this study in order to
obtain uniform nucleosome spacing.
3.3 Fluorescently Labelling Nucleosomal Array DNA
In order to detect the PD-1/H2B nucleosomal array, it was necessary to fluores-
cently label the DNA which contains 16 repeats of the Widom 601 nucleosome
assembly sequence. DNA was labelled using the Mirus Label IT® Nucleic Acid
Labelling Kit, Cy®3. This was performed by Dr. Jeong Park. Fluorescent la-
belling was selected as it is efficient and can be quantified directly and easily.
Fluorophores are able to attach to multiple sites on the nucleosomal array DNA
which ensures amplification of signal.
After determining the optimal ratio of histone octamers to DNA, it was then
necessary to compare PD-1-H2B nucleosomal assemblies made with both Cy3
labelled DNA and unlabelled DNA to determine whether the fluorophore labelling
affected nucleosome positioning, or causes DNA to aggregate such that the arrays
can no longer be cleaved by MNase. For this experiment, 0.75 µg of octamers
were mixed with 1 µg of unlabelled DNA as this was the optimal ratio determined
from Figure 3.10. This was compared to nucleosomal arrays assembled with
different amounts of PD-1/H2B octamers and 1 µg of Cy3-labelled DNA. All
assemblies were MNase digested, DNA isolated and fragments were resolved on
a 1.2% agarose gel.
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Figure 3.11: Micrococcal Nuclease Digestion of Unlabelled and Cy3 Labelled
Nucleosomal Arrays. MNase assay of nucleosomal arrays using 1µg/µL of unlabelled
pUC19 plasmid DNA and Cy3 labelled pUC19 plasmid DNA containing 16 repeats of
the Widom 601 nucleosome positioning sequence, and increasing amounts of PD-1-H2B
histone octamers as indicated. After mixing, assemblies were digested with 0.5 and 2
U/µL of MNase. DNA fragments were resolved on a 1.2% agarose gel and stained with
ethidium bromide. DNA ladder was run adjacent to the samples.
As seen in Figure 3.10, an array assembled using unlabelled DNA with PD-1-
H2B histone octamers resulted in a distinctly spaced DNA ladder, indicating
appropriate nucleosome spacing. When comparing this to nucleosomal arrays
assembled using Cy3 labelled DNA, however, there were indications that Cy3
affects nucleosomal array formation. MNase digestion of nucleosomal arrays made
with unlabelled DNA (lanes 1 and 2) show the distinctive ladder as seen in lanes
5 and 6 in Figure 3.10. The lack of distinct bands in lanes 3-8 (Figure 3.11) is
comparable to previous assemblies made with 0.25 µg of the PD-1/H2B histone
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octamers (Figure 3.10 lanes 1 and 2) which are under-saturated with histones.
Very faint bands can be seen in lanes 7 and 8 (Figure 3.11), but the lack of distinct
bands suggests that this assembly does not have correctly phased nucleosomes.
This suggests that the Cy3 label affects nucleosomal array formation.
Labelling DNA with a Cy3 fluorophore and forming nucleosomal arrays using
lower amounts of PD-1/H2B octamers does not form correctly phased nucleo-
somes (Figure 3.11) as using 0.75 µg of PD-1/H2B octamers did not result in a
discernible ladder. Next, it was questioned whether this type of fluorescent la-
belling required higher amounts of histone octamers for the DNA backbone to be
saturated with nucleosomes. Nucleosomal arrays were assembled using 0.75 µg to
1.50 µg of PD-1/H2B histone octamers and Cy3 labelled DNA. Arrays were made
using salt gradient buffer dialysis, and were digested with MNase. Detection of
the DNA ladder was achieved by exciting the Cy3 fluorophore instead of staining
agarose gels with ethidium bromide to confirm the ability to detect fluorescent
nucleosomal arrays.
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Figure 3.12: Micrococcal Nuclease Digestion of Cy3 Assemblies and Cy3
Labelled DNA. MNase assay of nucleosomal arrays using 1µg of Cy3 labelled pUC19
plasmid DNA and increasing amounts of PD-1-H2B histone octamers as indicated, or
1 µg of Cy3-labelled pUC19 DNA alone (0 µg). Assemblies were digested with 0.5 and
2 U/µL of MNase. DNA fragments were resolved on a 1.2% agarose gel. Fluorescence
images were captured on the Azure c600 software using the Cy3 channel (Ex: 554 nm,
Em: 568 nm).
From Figure 3.12, using 0.75 µg (lanes 1 and 2) of PD-1/H2B octamers did not
result in a discernible ladder, unlike the digests in Figure 3.10 using the same
amount of histone octamer. This is also the case when assemblies are made with
1 µg of PD-1/H2B octamers. The smearing of the DNA ladder in all assembly
lanes appear similar, though with much less intensity, to DNA alone (lanes 9 and
10). This indicates that the assemblies were likely under-saturated with histones
as using either concentration of MNase gives the same smear. When higher
amounts of histone octamers were used however, not only is there no discernible
ladder, but there is also DNA aggregation in the wells regardless of whether a
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higher concentration of MNase was used (lanes 5-8). This is likely caused by the
increased histone amount (1.25 µg and 1.50 µg). There is also DNA aggregation
in the DNA only (0 µg of PD-1/H2B) lanes 9 and 10. This may also indicate that
the PD-1 tag on the N-terminal of histone H2B could be affecting nucleosome
formation.
To investigate whether the H2B tagged with PD-1 affects the formation of nucle-
osomes, assemblies were made using 1 µg of Cy5-labelled nucleosome positioning
DNA and 0.75 µg of WT histone octamers. Assemblies were dialysed in decreasing
salt buffers and digested with MNase as in previous experiments. DNA fragments
were resolved on a 1.2% agarose gel and the fluorescence image captured using
Azure c600 software using the Cy3 channel.
Figure 3.13: Micrococcal Nuclease Digestion of Cy3 and Cy5 Nucleosomal
Arrays. MNase assay of nucleosomal arrays using 1µg of Cy3 or Cy5 labelled pUC19
plasmid DNA containing 16 repeats of the Widom 601 nucleosome positioning sequence
and 0.75 µg WT octamers. Assemblies were digested with 0.5 and 2 U/µL of MNase.
DNA fragments were resolved on a 1.2% agarose gel. Fluorescence images were captured
on the Azure c600 software using the Cy3 and Cy5 channels.
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Figure 3.13 shows that nucleosomal arrays made using 0.75 µg of PD-1/H2B
histone octamers and either Cy3 or Cy5 labelled DNA results in a smear of DNA,
indicating that nucleosomes are not correctly phased, if formed at all. This is
similar to Figure 3.12 when using 0.75 µg of PD-1/H2B histones. These findings
demonstrate that nucleosomal arrays made with either Cy3 or Cy5 labelled DNA
did not form properly positioned nucleosomal arrays. Due to this inconsistency,
a non-fluorophore label was tested in order to detect DNA.
Given the above issues, the pUC19 plasmid containing 16 Widom sequence re-
peats was biotin labelled, then bound with Avidin-Alexa 488 to enable fluores-
cence detection. Biotin labelling was performed using the EZ-Link® Psoralen-
PEG3-Biotin kit. A nucleosomal array was assembled using 5 µg of biotin-labelled
pUC19 plasmid and 3.75 µg of PD-1/H2B octamers as per Section 2.6.1. To con-
firm nucleosomal array formation, a MNase assay was performed and visualised.
As seen in Figure 3.14, there is a distinct DNA ladder when using a lower con-
centration of MNase indicating appropriate nucleosomal array formation.
Nucleosomal arrays formed with PD-1/H2B octamers and biotin-labelled DNA
formed correctly spaced nucleosomes and this array was used to test binding
to PD-L1 on the surface of cells. To determine if nucleosomal arrays had the
distinct "beads on a string" structure (Olins and Olins, 1974), they were visualised
by transmission electron microscopy (TEM). PD-1/H2B-biotin and WT-biotin
nucleosomal arrays were formed using the salt buffer dialysis method (as per
Section 2.6.1) and then stained with 2% uranyl acetate and 1% phosphotungstic
acid.
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Figure 3.14: Micrococcal Nuclease Digestion of Biotin-Labelled Nucleosomal
Arrays. MNase assay of a nucleosomal array made using 1µg/µL of biotin-labelled
pUC19 plasmid DNA containing 16 repeats of the Widom 601 nucleosome positioning
sequence and 0.75 µg of PD-1-H2B histone octamers. The assembly was digested with
0.5 and 2 U/µL of MNase. DNA was ethanol precipitated, after which they were resolved
on a 1.2% agarose gel and stained with ethidium bromide.
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Figure 3.15: TEM Images of WT and PD-1-H2B Assemblies. TEM images of
WT and PD-1-H2B assembled nucleosomal arrays using 5µg of biotin-labelled pUC19
plasmid DNA and 3.75 µg of WT (A) or PD-1-H2B histone octamers (B) diluted to 0.2
ng/µL. Assemblies were then incubated on a carbon-coated graphite grid and stained
with 2% uranyl acetate for 5 minutes followed by staining with 1% phosphotungstic
acid. Samples were then imaged using FEI Tecnai G2 Spirit BioTWIN transmission
electron- microscope. Scale bar: 100 nm
Unfortunately, Figure 3.15 shows both WT and PD-1/H2B nucleosomal arrays
do not exhibit the "beads on a string" structure (Baldi et al., 2020). Instead
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the arrays aggregate and this is likely due to preparation of the samples. Both
Figure 3.15A and Figure 3.15B show some distinct punctate spots indicated by
red arrows in both images, however it does not demonstrate an array structure
was formed. As WT and PD-1/H2B nucleosomal arrays both look similar, it can
be assumed that the PD-1 tag on the N-terminal tail of histone H2B is not the
cause of the aggregation. There are ways to overcome aggregation issues when
preparing nucleosomal arrays for TEM such as sonication of samples before they
are imaged, or dialysing samples over a longer period of time in a different salt
buffer (Guo and Cole, 1989).
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Chapter 4
Testing of PD-1 Nucleosomal Array
to Detect PD-L1 on the Cell Surface
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4.1 Selection of Cell Lines
To test the efficacy of PD-1/H2B nucleosomal array binding to PD-L1 on the
cell surface, two mammalian cell lines with low and high PD-L1 expression were
used to determine if there was differential binding of the PD-1/H2B nucleosomal
array. Initially, the Protein Atlas database (The Human Protein Atlas, 2021) was
screened to identify potential cell lines for this study. Figure 4.1A indicates the
highest PD-L1 protein levels are in glioma cell lines U138-MG, U251-MG, and
U87-MG. Amongst the lowest expressing cell lines are sourced from pancreatic
cancer cells, kidney and bladder cancer cells, MCF-7 breast cancer cells and Hela
cervical cancer cells. In order to confirm results from Protein Atlas, RT-qPCR was
performed (see Section 2.2) on a selection of cell lines (Figure 4.1B). U87-MG had
the highest PD-L1 mRNA expression levels followed by LN18. Cell lines H1299,
U2OS, and HeLa were also tested and showed moderate to low expression, with
MCF-7 showing the lowest mRNA expression level. This is in concordance with
in Figure 4.1A. Because MCF-7 and U87-MG cells showed the lowest and highest
PD-L1 expression respectively, these cell lines were chosen to test nucleosomal
array binding, and compare this binding to that of a diagnostic PD-L1 antibody.
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Figure 4.1: Cell Line Selection Process. (A) PD-L1 protein expression data
in cell lines. Data taken from The Human Protein Atlas, (B) RT-qPCR analyses of
different cancer cell lines. Cells were harvested after reaching 80-90% confluency, total
cell RNA was extracted, and 100 ng of RNA was used in each reaction containing PD-L1
primers. RT-qPCR reactions were analysed using the Roche 480 Lightcycler. Results
were normalised to β-Glucuronidase (GUS-β). Data was graphed using Graphpad Prism
software. 50
4.2 Developing PD-L1 Staining Using PD-1/H2B
Nucleosomal Arrays
To determine if the staining pattern of PD-1/H2B nucleosomal arrays was com-
parable to that of an antibody directed against PD-L1, the commercial DAKO
28:8 monoclonal antibody was used to stain both MCF-7 and U87-MG cells. This
antibody is used in IHC assays to determine if patients are viable for PD-L1 im-
munotherapy (Cogswell et al., 2017) and recognises the extracellular domain of
PD-L1 (Phe19-Thr239).
U87-MG and MCF-7 cells were both grown to 80-90% confluency before being
fixed and incubated with DAKO 28:8 PD-L1 antibody at a concentration of 2.85
µg/mL. Antibody staining was then detected by immunofluorescence (see Section
2.7). Representative images of both U87-MG and MCF-7 cells (Figure 4.2) show
that PD-L1 expression is localised to the surface of the cell, and not within the
cytoplasm or nucleus of the cell in Figure 4.2B or Figure 4.2F. While the general
trend is that U87-MG cells show slightly higher fluorescence than MCF-7 cells
(Figure 4.2D and 4.2F), it is not clear from this staining. Other fields of MCF-7
and U87-MG cells can be seen in Figure A.3 in the appendix.
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Figure 4.2: Immunofluorescence of MCF-7 and U87-MG Cells. MCF-7 cells
(A-D) and U87-MG cells (E-H) were incubated with 2.85 µg/mL of PD-L1 antibody
(green) overnight at 4◦C with rocking, after which they were washed and incubated
with anti-rabbit Alexa 555 to detect PD-L1 antibody and 1 µg/mL of Hoechst 33342
(blue) to stain nuclear DNA, (A & E), representative cell magnified 2.5x of (C & G),
scale bar: 25 µm. 52
To test if the PD-1/H2B nucleosomal array binds specifically to PD-L1 on the
surface of U87-MG and MCF-7 cells, the cells were grown to 80-90% confluency
before being harvested and fixed. After fixation, cells were incubated with 1 µg of
PD-1/H2B nucleosomal array for 1 hour at room temperature and stained with
2 µg of Avidin-488 conjugate to bind to biotin-labelled nucleosomal array DNA,
or 2 µg of Avidin-488 conjugate alone for 30 minutes at room temperature in the
dark to avoid photo-bleaching. Hoechst 33342 was used to stain nuclear DNA as
it is water soluble and cell permeable, thus permeabilisation of the cells was not
required (see Section 2.7.3).
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Figure 4.3: Avidin 488 Conjugate Binds Non-Specifically to the Outside
of MCF-7 and U87-MG Cells. Fluorescence images of U87-MG and MCF-7 cells
incubated with either 2 µg of Avidin 488 Conjugate or 1 µg of PD-1/H2B assembly
and 488 conjugate. Nuclear DNA was stained with 1 µg/mL of Hoechst 33342 and
PD-1/H2B arrays were visualised using Avidin 488 conjugate. In the merged images,
DNA is blue and Avidin 488 conjugate is green, scale bar: 25 µm. PDR, PD-1/H2B
nucleosomal arrays.
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Figure 4.3 shows no detectable difference in staining intensity or localisation
between MCF-7 cells incubated with Avidin-488 conjugate only (Figure 4.3B)
and PD-1/H2B nucleosomal array (Figure 4.3E) as the staining intensity is low
for MCF-7 cells incubated with Avidin-488 conjugate or PD-1/H2B nucleosomal
arrays. As U87-MG cells incubated with Avidin-488 conjugate only (Figure 4.3H)
and PD-1/H2B nucleosomal arrays (Figure 4.3K) resemble what is seen in MCF-7
cells, this indicates non-specific binding of the Avidin-488 conjugate to the surface
of the cells.
As the results in Figure 4.3 showed no specific PD-1/H2B nucleosomal array bind-
ing in either cell line, it was questioned whether pre-incubation of PD-1/H2B
nucleosomal arrays with Avidin-488 conjugate prior to staining of the cells re-
moves background non-specific binding of Avidin-488 conjugate on the surface of
the cell. Prior to incubating cell lines with PD-1/H2B nucleosomal array, 1 µg of
nucleosomal array was incubated with 2 µg of Avidin-488 conjugate for 2 hours at
room temperature in the dark. During this time, U87-MG and MCF-7 cells were
fixed after which they were stained with Avidin-488 mixed PD-1/H2B assemblies,
or Avidin-488 conjugate alone.
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Figure 4.4: Incubation of Cells with Avidin-488 Pre-incubated PD-1/H2B
Nucleosomal Arrays Results in Non-Specific Binding. Fluorescence images of
U87-MG and MCF-7 cells incubated with either 2 µg of Avidin-488 conjugate or 1 µg
of PD-1/H2B nucleosomal array (PDR). Nuclear DNA was stained with 1 µg/mL of
Hoechst 33342 and Avidin-488 conjugate was used to detect biotin-labelled nucleosomal
array DNA. In the merged images, DNA is blue and Avidin-488 conjugate is green, scale
bar: 25 µm. PDR, PD-1/H2B nucleosomal arrays.
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Figure 4.4 shows no detectable difference in staining intensity or localisation
between MCF-7 cells incubated with Avidin-488 conjugate only (Figure 4.4B)
and PD-1/H2B nucleosomal array (Figure 4.4E) as the staining intensity is low
for MCF-7 cells incubated with Avidin-488 conjugate or PD-1/H2B nucleosomal
arrays (Figure 4.4E). U87-MG cells incubated with PD-1/H2B assemblies do
not show specific localisation of PD-1/H2B arrays (Figure 4.4K) as they closely
resemble cells incubated with Avidin-488 conjugate alone (Figure 4.4H). Further
to this, there is no difference in intensity between MCF-7 and U87-MG cells
stained with PD-1/H2B assemblies, though U87-MG cells would be expected
to have higher PD-L1 expression. While these results do not show significant
changes from that of the previous experiment in which cells were incubated with
PD-1 assemblies before being stained with Avidin-488 conjugate (Figure 4.3), pre-
incubation of PD-1/H2B nucleosomal arrays was used during the remainder of
the study to fluorescently label the PD-1/H2B nucleosomal arrays before applying
them to cells.
As there remained non-specific binding of Avidin-488 conjugate, herring sperm
DNA was used as a non-specific competitor to reduce background staining (Lee
et al., 2015). As U87-MG cells highly express PD-L1, these cells were fixed
and incubated with 100 µg/mL of herring sperm DNA in blocking buffer for 30
minutes, and then incubated with 1 µg of either DNA, Avidin-488 conjugate, WT
or PD-1/H2B assemblies all of which were pre-incubated with 2 µg of Avidin-488
conjugate (see Section 2.7.3).
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Figure 4.5: Herring Sperm Disrupts Both WT and PD-1/H2B Arrays Bind-
ing to U87-MG Cells. Fluorescence images of U87-MG cells incubated with 100
µg/mL of herring sperm DNA and 1 µg of biotin labelled pUC19 DNA, 2 µg of Avidin-
488 conjugate, 1 µg of WT assembly, or 1 µg of PD-1/H2B nucleosomal array (PDR).
Nuclear DNA was stained with 1 µg/mL of Hoechst 33342 and Avidin-488 conjugate
was used to visualise biotin-labelled nucleosomal array DNA. In the merged images,
DNA is blue and Avidin-488 conjugate is green, scale bar: 25 µm. PDR, PD-1/H2B
nucleosomal arrays. 58
As seen in Figure 4.5, incubation of U87-MG cells with herring sperm DNA
resulted in little discernible background staining in the Avidin-488 channel when
U87-MG cells were incubated with the biotin labelled pUC19 DNA. Staining
intensity was low on U87-MG cells incubated with Avidin-488 only (Figure 4.5E)
and WT nucleosomal array (Figure 4.5H) as the octamers contain untagged H2B.
However, herring sperm DNA also abrogates binding of PD-1/H2B nucleosomal
arrays to cells (Figure 4.5K). This lack of staining indicates that the PD-1/H2B
array did not bind to PD-L1 on the cell surface. The reason it is possibly due to
the addition of the non-specific competitor, and hence herring sperm DNA was
not be used in further assays.
As addition of herring sperm DNA hindered PD-1/H2B array binding, the wash-
ing buffer components were investigated next. In Figure 4.2, cells were washed
with a PBS buffer containing 0.1% Triton X-100, a non-ionic detergent. It was
hypothesised that the buffer may be too harsh to allow PD-1/H2B arrays to re-
main bound on the outside of the cell. Hence it was investigated whether the
absence of this detergent in the wash buffer increases PD-1/H2B nucleosomal
array binding to PD-L1 on the outside of MCF-7 and U87-MG cells. Both cells
lines were incubated with PD-1/H2B assemblies and WT assemblies pre-mixed
with Avidin-488 conjugate, or Avidin-488 conjugate alone for 1 hour at room tem-
perature in the dark. After incubation, cells were only washed with PBS once
after staining and fixed again (see Methodology 2.7.3). Figures 4.6 and 4.7 show
the brightfield and fluorescence images captured for both MCF-7 and U87-MG
cells respectively.
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Figure 4.6: PDR Nucleosomal Arrays do not Detect PD-L1 on the Outside
of MCF-7 Cells. Fluorescence images of MCF-7 cells incubated with 2 µg of Avidin
488 conjugate, 1 µg of WT assembly, or 1 µg of PD-1/H2B nucleosomal array (PDR).
After fixation and mounting, cells were imaged in brightfield DIC (left) and Avidin-488
was used to detect biotin-labelled nucleosomal array DNA. Merged images show PDR
assembly as green, scale bar: 25µm. PDR, PD-1/H2B nucleosomal arrays.
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Figure 4.7: PDR nucleosomal Arrays Bind Detect PD-L1 on the Outside of
U87-MG Cells. Fluorescence images of U87-MG cells incubated with 2 µg of Avidin
488 conjugate, 1 µg of WT assembly, or 1 µg of PD-1/H2B nucleosomal array (PDR).
After fixation and mounting, cells were imaged in brightfield DIC (left) and Avidin-488
was used to detect biotin-labelled nucleosomal array DNA. Merged images show PDR
assembly as green, scale bar: µm. PDR, PD-1/H2B nucleosomal arrays.
Figure 4.6 shows that for MCF-7 cells, there is no discernible staining between
cells incubated with either Avidin 488 (Figure 4.6B), WT assembly (Figure 4.6E),
or PD-1/H2B assembly (Figure 4.6H). It can therefore be concluded that there is
non-specific binding of PD-1/H2B array to PD-L1 on the cell surface of MCF-7
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cells, even without detergent in the wash buffer. However, there was no non-
specific binding of the Avidin-488 conjugate. Other fields of cells are shown in
Figure A.4.
Figure 4.7 shows representative images of U87-MG cells treated in the same fash-
ion as MCF-7 cells in Figure 4.6. The lack of staining in Figures 4.7B and 4.7E
indicate there is no specific binding of either Avidin 488 alone, or WT assembly
which is what is expected as neither contain a PD-1 peptide to bind to PD-L1.
However, Figure 4.7H, however, shows a distinct staining pattern of punctate
foci on the surface of the cells. The merged image (Figure 4.7I) illustrates that
this staining is not present within either in the cytoplasm or the nucleus (other
fields of cells are shown in Figure A.3). This would indicate that PD-1/H2B array
bound specifically to the outside of high PD-L1 expressing U87-MG cells and that
nucleosomal arrays are able to detect differential PD-L1 expression between cell
lines as MCF-7 cells lacked this staining. This staining pattern is distinguishable
from either negative control WT nucleosomal arrays and the Avidin-488 conju-
gate alone. Therefore PD-1/H2B nucleosomal arrays can detect PD-L1 on the
surface of U87-MG cells. Other fields of cells are shown in Figure A.5.
4.3 Using PD-1/H2B Nucleosomal Arrays in Other
Assays
The use of the PD-1/H2B nucleosomal arrays in other formats was also tested.
However, due to time constraints, this was unable to be completed. Initially flu-
orescence was measured using the Roche 480 Lightcycler as a high throughput
method that enabled fast detection. U87-MG cells were harvested and incubated
with a range of differing amounts (0.5 µg to 5 µg) of either PD-1/H2B assembly,
or WT nucleosomal arrays assembled with Cy5-labelled pUC19 DNA. As shown
in Figure 4.7, U87-MG cells incubated with higher amounts of Cy5 PD-1/H2B
assembly emitted greater fluorescence than those cells stained with WT nucleo-
somal arrays. This indicates that not only is the emitted fluorescence from the
array able to be captured, but that the fluorophore-labelled PD-1/H2B binds to
cells through the PD-L1/PD-1 interaction as any unbound assembly was removed
through a series of washing steps. The more PD-1/H2B assembly that is added
62
to the cells, the greater the fluorescence capture. This is especially noticeable
with those cells incubated with 5 µg of this assembly. This may further indicate
that there is a ‘minimum’ amount of array needed in order to bind PD-L1 on the
surface of tumour cells, and to detect a significant difference between stained and
unstained cells. Given that this assay was done with Cy5 labelled DNA that does
not form properly spaced nucleosomes (Figure 3.13), this assay needs to be re-
peated with PD-1/H2B nucleosomal arrays made with biotin-Avidin-488 labelled
DNA. WT assembly made using Cy5-labelled pUC19 plasmid DNA.
Figure 4.8: PD-1/H2B-Cy5 Nucleosomal Arrays Bind Selectively to U87-
MG Cells. U87-MG cells were re-suspended at a density of 5 x 106 cells/mL, after
which 0, 0.1 µg, 0.5 µg, 1 µg, 2 µg, or 5 µg of Cy5-PD-1/H2B nucleosomal array or
Cy5-Wild Type nucleosomal array was applied. U87-MG cells were incubated at room
temperature in the dark for 2 hours, after which they were washed and 20 µL of each
reaction was transferred to a 96 well plate. Fluorescence was captured using the Roche
480 Light Cycler using the Cy5 filter (615 nm - 670 nm). The program for this assay is
detailed in Section 2.8.1.
Fluorescence activated cell sorting (FACS) was also used to test whether there
was a detectable difference in the fluorescence capture of PD-1/H2B nucleosomal
arrays made with Cy3-labelled DNA between high and low PD-L1 expressing
tumour cell lines U87-MG and MCF-7 cells respectively. These cell lines were
harvested and 5 x 104 of cells were incubated with either with 0.1 µg, 0.5 µg or
1 µg of PD-1/H2B-Cy3 nucleosomal arrays for two hours after which fluorescent
cell populations were separated using FACS. The PE filter was used to detect
the Cy3 fluorophore, and the FITC filter was used to capture any fluorescence
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emitted at a lower wavelength.
Figure 4.9: Differences Between Stained and Unstained Cell Populations are
Indistinguishable Using FACS. U87-MG and MCF-7 cells were grown to 80-90%
confluency and resuspended at a density of 5.0 x 105 cells/mL. Cells were left unstained
or incubated with 1 µg of Cy3-PD-1/H2B arrays for 30 minutes and fixed, after which
cell populations were separated using FACS. These are indicated by the gates on the
left of each image. PE: R-phycoerythrin filter (Ex 566 nm Em 574), FITC: fluorescein
filter (Ex 490 nm, Em 525 nm).
Analysis of stained and unstained MCF-7 and U87-MG cell populations revealed
no significant difference either between Cy3-PD-1/H2B nucleosomal array stained
cells and unstained cells, or between cell lines. Unstained cells used as negative
controls revealed that only a small fraction of unstained MCF-7 (0.056%) and
U87-MG (0.021%) of cells emitted detectable fluorescence as shown in the gates.
However, 4.4% of stained MCF-7 cells and 3.7% of U87-MG cells stained posi-
tive for the Cy3 fluorophore (PE detector). The small percentage of stained cells
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suggests that the PD-1/H2B nucleosomal arrays did not bind to PD-L1 on the
surface of the cells. These results indicate that the cells may need longer incu-
bation time with the array, or more of the array in order to observe a detectable
difference in cell populations.
As Cy3 and Cy5 labelled DNA was the only labelling system available in the
laboratory at the time, it was used to assemble the nucleosomal arrays used above.
Subsequently, as shown in Figure 3.12 and Figure 3.13, it was determined that the
Cy3 and Cy5-labelled arrays do not form properly spaced nucleosomes. These
protocols still requires further optimisation. Initially, biotin-PD-1/H2B arrays
will be used alongside WT assemblies and Avidin-488 only negative controls.
After being optimised in U87-MG cells, these assays would then be performed on
MCF-7 cells to detect whether there is differential binding of PD-1/H2B arrays
between low and high PD-L1 expressing cell lines.
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Chapter 5
Discussion and Future Directions
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5.1 Forming Peptide Tagged Nucleosomal Arrays
This research investigated whether the core histone H2B, with a receptor domain
at its N-terminal tail could, along with the other core histones and fluorescently
labelled DNA, form a nucleosomal array and whether this then binds to a ligand
on the cell surface and be detected. This is a high affinity interaction that should
increase specificity than that of antibodies.
As proof of principle, this study utilised the reaction that occurs endogenously
between PD-L1 and PD-1 by incorporating the extracellular domain of PD-1,
which binds to PD-L1, on the N-terminal tail of histone H2B. Accurately deter-
mining the presence of PD-L1 on the surface of cells is of importance as PD-L1
over-expression is used as a predictive bio-marker to determine whether patients
are viable for PD-L1/PD-1 immunotherapy. IHC assays are the standard diagnos-
tic method to determine PD-L1 expression levels on patient histological samples.
However, the PD-L1 antibody used varies between diagnostic laboratories, and
the performance of these antibodies also differs greatly (Torlakovic et al., 2020;
Kintsler et al., 2019; Schats et al., 2018). Using the PD-1 extracellular domain
to detect the level of PD-L1 on cancer cells should overcome this issue.
A protocol for fluorescent confocal microscopy was developed to test if PD-1
containing array bound specifically to the surface of U87-MG cells. PD-1/H2B
containing nucleosomal arrays bound specifically to the surface of U87-MG cells
while control WT nucleosomal arrays and Avidin-488 alone did not adhere to
the surface of cells. PD-1/H2B nucleosomal arrays did not bind to the surface
of MCF-7 cells, indicating that these arrays were able to differentially detect
PD-L1 expression levels between cell lines. It was necessary for biotin to be pre-
bound with Avidin-Alexa-488. When added after PD-1/H2B nucleosomal arrays
were incubated with cells, there was non specific background staining. Thus,
pre-incubating assemblies first and washing away excess reduced background non-
specific binding. Coupling this method with washing cells in a non-ionic detergent
wash buffer also improved staining intensity.
Though the presence of the PD-1 peptide tag on the N-terminal tail of histone
H2B did not affect nucleosomal array formation, the method of fluorescently
labelling DNA was important. Using biotin labelled DNA had correct nucleosome
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phasing whereas using Cy3 or Cy5 labelled DNA did not work as nucleosomes
were not positioned properly. Studies have shown that Cy3 and Cy5 fluorophores
when present in the DNA prevented DNA bending. They have high affinity
to TA base pairs which lie in the minor groove of DNA where there is greater
distortion of DNA that is energetically unfavourable (Balasubramanian et al.,
2009; Morozov et al., 2009). The fluorophore acts as an additional base pair that
straightens DNA and reduces the ability of other base pairs to roll freely (Spiriti
et al., 2011). As the Widom sequence contains these TA base pairs to allow it
to bend and position nucleosomes, labelling with Cy3 or Cy5 likely hinders this
ability. This is the probable reason for the lack of properly phased nucleosomes
and nucleosome formation that was encountered when using these fluorophores.
5.2 Benefits of Nucleosomal Arrays
Nucleosomal arrays can vary in length with the number of nucleosomal repeat
sequences in the array. The nucleosomal arrays formed in this study contain
two H2B histone proteins per unit and so contain 32 potential binding sites for
PD-L1. This increases the ability to detect PD-L1 on the surface of cells. IgG
antibodies have only two epitope binding sites (Janeway Jr et al., 2001). As
the nucleosomal arrays formed in this study all contain the same receptor-tagged
H2B, these assemblies will only recognise PD-L1 on the surface of the cells. Fur-
ther to this, the ability to label the DNA at multiple sites allows greater signal
amplification rather than a fluorophore-conjugated primary or likely fluorophore-
conjugated secondary antibody. In addition, nucleosomal arrays are relatively
easy to produce whereas antibody production can be expensive.
However, using PD-1/H2B nucleosomal arrays to detect protein on the surface
of a cell still has the same staining and scoring issues the IHC assays. The
staining pattern could depend on the preparation of samples and the formation
of the nucleosomal arrays. Further to this, different scoring matrices between
diagnostic laboratories may give different conclusions of whether patients need
to undergo PD-L1/PD-1 immunotherapy. Future optimisations may help reduce
these concerns with further improvements on nucleosomal array formation and
enhanced staining protocols.
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Currently there are two commercially available PD-L1 IHC assay kits (Ventana
PD-L1 Assay, Roche Diagnostics and PD-L1 22C3, pharmDx, Aligent) each with
their own scoring algorithm and protocol, with different PD-L1 antibodies utilised
in the assay. These antibodies recognise different PD-L1 splicing variants, some
of which may be preferentially present in different tumour types. Not all PD-L1
antibodies used in the diagnostic IHC assays are able to recognise different PD-L1
splicing variants expressed on a patient histological sample. This suggests that
PD-L1 IHC assays are not interchangeable, and can pose a risk to patient health
if it is concluded that they are not viable for PD-L1-PD-1 immunotherapy based
on which IHC assay was used.
Other PD-L1 isoforms exist that are secreted from the cell and homo-dimerise.
Studies investigating this phenomenon have shown the addition of an 18 amino
acid domain facilitates bending and homo-dimerization (Mahoney et al., 2019).
This secreted form of PD-L1 has also been shown to correlate with clinically
aggressive non-small cell lung cancer and renal cell carcinoma (Takeuchi et al.,
2018; Frigola et al., 2011). Not all PD-L1 antibodies used in IHC will be able to
recognise this secreted form of PD-L1. PD-1/H2B nucleosomal arrays are able
to overcome this issue as different fragments of the PD-1 receptor are able to
be fused to different histone N-terminal tails. This would allow the nucleosomal
arrays to detect secreted PD-L1 and different PD-L1 splicing variants unlike a
monoclonal PD-L1 antibody.
5.3 Future Directions
To confirm that these nucleosomal arrays are able to detect differential PD-L1
expression on cancer cells, the assemblies need to be tested on a range of cells
lines with known PD-L1 expression. Future optimisations will include testing PD-
1/H2B nucleosomal arrays on other cell lines. This will help further demonstrate
that these nucleosomal arrays are able to detect differential PD-L1 expression
on cancer cells sourced from other tumour types. Nucleosomal array formation
may be further optimised by investigating the dialysis buffer used to form the
assemblies. All nucleosomal assemblies made in this study were dialysed in NaCl
gradient buffers. Including K+ and Mg2+ abrogates formation of the 30 nm
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chromatin fibre (Allahverdi et al., 2015) and dialysing nucleosomal assemblies in
different ionic buffers, or a mixture of ionic buffers, should be investigated in the
future. This may also help with the visualisation of the nucleosomal arrays using
TEM.
5.3.1 Optimising the Detection of PD-L1
In this study, only histone H2B was tagged with the extracellular domain of PD-
1. In the future, nucleosomal arrays could be formed with all histones tagged
with PD-1. Forming nucleosomal arrays that contain all the core histones tagged
within the histone octamers may increase the binding to PD-L1 on the cell surface.
If the same number of repeats of the nucleosome positioning sequence is used, this
increases the number of potential binding sites to 128. No evidence suggests that
PD-1 homo-dimerises (Zak et al., 2015) and therefore it can be assumed that this
peptide tag would not be the cause of aggregation in these nucleosomal arrays.
Histone H2B N-terminal tails are needed for proper H2A/H2B dimer formation
and therefore nucleosome formation (Thiriet and Hayes, 2001; Mao et al., 2016).
Not only does tagging H2B N-terminal tails have no adverse effects on nucleoso-
mal array formation, the other core histone N-terminal tails are dispensable for
compaction (de la Barre et al., 2001). In the future, decreasing or increasing the
number of Widom sequence repeats will be investigated. Increasing the number
of tagged histones may require a smaller number of Widom 601 repeats. It may
be that using both PD-1 tagged H2A/H2B dimers and a shorter nucleosomal ar-
ray improves binding and prevents aggregation, and a more significant difference
may be detected between different cell lines. As the same plasmid will be used,
the biotin-labelling should not be greatly reduced so signal amplification would
not decrease.
It has been well established that over-expression of PD-L1 is linked to poor prog-
nosis of cancer patients while there is less evidence to suggest that PD-L2 ex-
pression is associated with patient prognosis compared to PD-L1. Interestingly,
PD-L2 binds to PD-1 with three times higher affinity than PD-L1 and yet PD-L1
and PD-L2 share only 39% amino acid identity. It is speculated higher affinity is
due to the presence of a tryptophan residue at position 110 (W110) rather than
an alanine at position 121 in PD-L2 and PD-L1 respectively (Viricel et al., 2015).
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Some reports have noted the tryptophan replacement weakens affinity of PD-L2
to PD-1, and that affinity in increased due to the presence of a flexible loop region
that latches onto PD-1, preventing W110 from inhibiting the interaction (Philips
et al., 2020). As this interaction is much stronger than that of PD-L1 to PD-1,
it would be interesting to investigate whether PD-1/H2B nucleosomal arrays also
to bind to PD-L2 on the surface of cancer cells.
5.4 Other Platforms for Detection
This PD-1/H2B nucleosomal array also needs to be optimised for use in other
formats. For example, FACS can be developed for cells in suspension with arrays
containing the Alexa-488-biotin assemblies, as per Figure 4.9, with appropriate
controls and duplicates. Other assays that use different formats for detecting the
fluorescence of this nucleosomal assembly can be developed such as those that
use plate readers to detect fluorescence and this would develop a high-throughput
screening method for PD-L1 expression.
The success of using the PD-L1/PD-1 endogenous interaction in these nucleoso-
mal arrays is indicative that alternate nucleosomal arrays could be formed that
target other extracellular proteins. A previous study used nucleosomal arrays to
display a Ras peptide to determine whether this raised an antibody response in
mouse models (Parlane et al., 2020). There was no disruption to nucleosomal ar-
ray formation when the Ras peptide was attached to all core histone N-terminal
tails. Although non-immunogenic, this does show that different nucleosomal ar-
rays can be formed with alternate peptides.
5.5 Summary
This study has shown that nucleosomal arrays are able to be formed with PD-1
receptor tagged H2B N-terminal tails and these arrays are able to be fluorescently
labelled using Avidin-Alexa-488-biotin. It was shown that tagging the N-terminal
tail of core histone H2B does not affect nucleosome formation but that the method
of fluorescently labelling the positioning DNA is important. A staining protocol
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was developed to demonstrate that the PD-1/H2B nucleosomal assemblies bind
to PD-L1 on the surface of U87-MG and that they detect differential expression
between cell lines. As this study used the high affinity endogenous PD-L1/PD-
1 interaction, it suggests that this system could also be used to detect other
extracellular proteins, and further development may result in an alternate staining
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Figure A.1: Full Gel Image of Figure 3.7. In Figure 3.7, the H2A-H2B-N-PDL
sample was omitted as this was not used for the experiments in this study. H2A-H2B-
N-PDL, PD-L1 ligand peptide attached to the N-terminal of H2B.
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Figure A.2: Full Gel Image of Figure 3.9. In Figure 3.9, lanes indicating the
previously made PD-1/H2B octamers were omitted to prevent confusion between them
and the recently formed PD-1/H2B octamers. Previously formed PD-1/H2B histone
octamers were purified and 1.00 µg was separated using 12% SDS-PAGE and stained
with Coomassie blue.
84
Figure A.3: MCF-7 and U87-MG Cells Express PD-L1 Differentially. MCF-7
cells (A-D) and U87-MG cells (E-H) were incubated with 2.85 µg/mL of PD-L1 antibody
(green) overnight at 4◦C with rocking, after which they were washed and incubated
with anti-rabbit and 1 µg/mL of Hoechst 33342 (blue) to stain nuclear DNA, (D & H),
representative cell magnified 2.5x of (C & G), scale bar: 25 µm.
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Figure A.4: Representative Images of PD-1/H2B Stained MCF-7 Cells. Flu-
orescence images of MCF-7 cells incubated with 2 µg of Avidin 488 conjugate, 1 µg
of WT assembly, or 1 µg of PD-1/H2B nucleosomal array (PDR). After fixation and
mounting, cells were imaged in brightfield DIC (left) and Avidin-488 was used to detect
biotin-labelled nucleosomal array DNA. Merged images show PDR assembly as green,
scale bar: µm.
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Figure A.5: Representative Images of PD-1/H2B Stained U87-MG Cells.
Fluorescence images of U87-MG cells incubated with 2 µg of Avidin 488 conjugate, 1
µg of WT assembly, or 1 µg of PD-1/H2B nucleosomal array (PDR). After fixation and
mounting, cells were imaged in brightfield DIC (left) and Avidin-488 was used to detect
biotin-labelled nucleosomal array DNA. Merged images show PDR assembly as green,
scale bar: µm.
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